1. Home
  2. TCRX vs CBAT Comparison

TCRX vs CBAT Comparison

Compare TCRX & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCRX
  • CBAT
  • Stock Information
  • Founded
  • TCRX 2018
  • CBAT 1999
  • Country
  • TCRX United States
  • CBAT China
  • Employees
  • TCRX N/A
  • CBAT N/A
  • Industry
  • TCRX Biotechnology: Pharmaceutical Preparations
  • CBAT Industrial Machinery/Components
  • Sector
  • TCRX Health Care
  • CBAT Miscellaneous
  • Exchange
  • TCRX Nasdaq
  • CBAT Nasdaq
  • Market Cap
  • TCRX 67.9M
  • CBAT 71.6M
  • IPO Year
  • TCRX 2021
  • CBAT N/A
  • Fundamental
  • Price
  • TCRX $1.44
  • CBAT $0.70
  • Analyst Decision
  • TCRX Strong Buy
  • CBAT
  • Analyst Count
  • TCRX 6
  • CBAT 0
  • Target Price
  • TCRX $9.83
  • CBAT N/A
  • AVG Volume (30 Days)
  • TCRX 520.8K
  • CBAT 192.3K
  • Earning Date
  • TCRX 05-12-2025
  • CBAT 05-09-2025
  • Dividend Yield
  • TCRX N/A
  • CBAT N/A
  • EPS Growth
  • TCRX N/A
  • CBAT N/A
  • EPS
  • TCRX N/A
  • CBAT 0.13
  • Revenue
  • TCRX $2,816,000.00
  • CBAT $176,614,609.00
  • Revenue This Year
  • TCRX $47.30
  • CBAT $28.79
  • Revenue Next Year
  • TCRX $74.30
  • CBAT $36.77
  • P/E Ratio
  • TCRX N/A
  • CBAT $5.42
  • Revenue Growth
  • TCRX N/A
  • CBAT N/A
  • 52 Week Low
  • TCRX $1.02
  • CBAT $0.57
  • 52 Week High
  • TCRX $9.69
  • CBAT $2.08
  • Technical
  • Relative Strength Index (RSI)
  • TCRX 49.74
  • CBAT 41.50
  • Support Level
  • TCRX $1.02
  • CBAT $0.63
  • Resistance Level
  • TCRX $1.36
  • CBAT $0.73
  • Average True Range (ATR)
  • TCRX 0.16
  • CBAT 0.06
  • MACD
  • TCRX 0.05
  • CBAT -0.00
  • Stochastic Oscillator
  • TCRX 77.78
  • CBAT 56.52

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

Share on Social Networks: